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Abstract
Background & Aims: Thrombocytosis is associated with more aggressive tumour bi-
ology in many malignancies. There are limited data in patients with hepatocellular 
carcinoma (HCC), which often occurs in patients with cirrhosis and portal hyperten-
sion. We aimed to explore the prognostic value of thrombocytosis in two cohorts of 
patients with HCC.
Methods: We included 3561 patients from Taiwan and 1145 patients from the USA. 
Thrombocytopenia was defined as platelet count < 150×109/L and thrombocytosis 
as ≥ 300 × 109/L at HCC diagnosis. We used multivariable Cox proportional hazard 
models to identify independent predictors of survival.
Results: Thrombocytosis was present in 9.0% and 6.9% of Taiwan and USA patients 
respectively. Compared to patients with normal platelet counts and those with 
thrombocytopenia, patients with thrombocytosis had larger tumours, increased vas-
cular invasion and a higher proportion had extrahepatic metastases in both cohorts. 
In multivariable analysis, thrombocytosis (aHR 1.40, 95% CI 1.23-1.60) and throm-
bocytopenia (aHR 1.13, 95% CI 1.04-1.23) were both associated with worse survival 
after adjusting for age, gender, liver disease aetiology, Child-Pugh score, maximal 
     |  2523LIU et aL.
1  | INTRODUC TION
With nearly 800 000 deaths annually, hepatocellular carcinoma 
(HCC) is the fourth leading cause of cancer-related mortality 
worldwide.1 HCC is highly lethal and has a poor prognosis as a re-
sult of the lack of chemoprophylactic agents among high-risk indi-
viduals, delays in detection, frequent presentation at late stages 
and high rates of recurrence with currently available therapies.2-5 
While the highest incidence rates of HCC are still reported in 
Southeast Asia and sub-Saharan Africa, the incidence of HCC in 
the USA has tripled over the past 20 years.6,7 While the mortality 
for most cancers in the USA is decreasing, HCC-related mortality 
continues to climb.6
Thrombocytosis is often considered as a paraneoplastic syn-
drome and is associated with poor prognosis in many types of ma-
lignancy such as ovarian cancer and gastric cancer.8,9 However, few 
data evaluating the prognostic value of platelet counts in patients 
with HCC, which typically arises in a background of cirrhosis, where 
thrombocytopenia is prevalent as a result of portal hypertension 
and splenic sequestration.10-14 The data that do exist have yielded 
conflicting information regarding the prognostic value of platelet 
counts. Thrombocytopenia has both been associated with increased 
HCC risk among patients with cirrhosis15 as well as worse survival 
among HCC patients.16,17 However, others have reported that 
thrombocytosis is associated with increased risk of vascular invasion 
and extrahepatic metastasis.18,19 Furthermore, antiplatelet therapy, 
such as aspirin, may be associated with a reduction in HCC risk20,21 
and lower recurrence rate and improved survival after surgical re-
section.22 Although the exact mechanism of this potential associa-
tion is unknown, some have speculated that it may relate to aspirin's 
antiplatelet properties. Finally, the data that do exist have largely 
been derived from HBV-predominant populations in Asia and there 
are less data including Western patient populations with other ae-
tiologies of liver disease such as HCV infection and alcohol-related 
liver disease.
To address this area of uncertainty, we performed a cohort 
study utilizing two large cohorts from Taiwan and the USA to ex-
amine the prognostic implications of thrombocytosis in patients 
with HCC.
2  | PATIENTS AND METHODS
2.1 | Patients
This study consisted of two cohorts—one from Taiwan and the 
other from the USA. The Taiwan cohort included 3561 con-
secutive patients with newly diagnosed HCC admitted to Taipei 
Veterans General Hospital between 2002 and 2017. The USA 
cohort was comprised of 1145 consecutive newly diagnosed, 
treatment-naïve HCC patients seen at the University of Texas 
Southwestern Medical Center or Parkland Health & Hospital 
System between 2008 and 2017. Detailed information regard-
ing the two cohorts has been reported previously.23,24 For both 
cohorts, HCC diagnosis was based on the American Association 
for the Study of Liver Diseases (AASLD) and the Asian Pacific 
Association for the Study of the Liver (APASL) guidelines at the 
time of HCC diagnosis.10,25 We excluded patients who did not 
meet AASLD or APASL criteria for HCC diagnosis or who were 
missing platelet count from the time of diagnosis. Patients were 
included independent of cirrhosis status, although prior data sug-
gest over 90% of all HCC patients have cirrhosis at time of diag-
nosis.26 The study protocols were approved by the Institutional 
Review Board of both institutions and complied with current 
ethical guidelines.
tumour size, tumour nodularity, vascular invasion, lymph node or distant metastasis, 
performance status and alpha-fetoprotein level. Patients with thrombocytosis had 
a median survival of 6 and 4 months in the Taiwan and USA cohorts, compared to 
32 and 14 months for those with normal platelet counts and 38 and 16 months for 
thrombocytopenic patients.
Conclusion: Thrombocytosis is independently associated with increased tumour bur-
den and worse overall survival among HCC patients.
K E Y W O R D S
liver cancer, platelet count, prognosis
Layman Summary
Thrombocytosis is independently associated with more 
advanced tumour stage and worse overall survival among 
patients with hepatocellular carcinoma. Our findings add 
to the growing literature about the complex interactions 
between platelet and hepatocellular carcinoma in patients 
with cirrhosis. Further translational studies are warranted 
in exploring the chemoprophylactic, prognostic and thera-
peutic roles of platelets and antiplatelet therapy among 
patients with hepatocellular carcinoma and patients at risk 
of hepatocellular carcinoma.
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2.2 | Data collection
Baseline patient characteristics including demographics, liver 
disease aetiology, the severity of cirrhosis, performance sta-
tus, complete blood count, serum biochemistries and serum 
alpha-fetoprotein were collected from the time of HCC di-
agnosis. The model for end-stage liver disease (MELD) and 
albumin-bilirubin (ALBI) scores and grades were calculated 
to assess the severity of liver dysfunction.27,28 Hepatitis B 
virus (HBV) infection was defined by the presence of hepa-
titis B surface antigen, and hepatitis C virus (HCV) infection 
was based on the presence of a positive anti-HCV antibody 
or RNA. We collected tumour burden including the number 
of nodules, maximum tumour diameter, presence of vascular 
invasion and evidence of lymph node or distant metastases. 
Tumour stage was determined according to the Barcelona 
Clinic Liver Cancer (BCLC) staging system.10,29 In both co-
horts, patients were followed up every 3-6 months until 
death, liver transplantation or lost to follow-up. In the Taiwan 
cohort, mortality was additionally confirmed via a nationwide 
National Cancer Registry.
Platelet count was recorded at the time of HCC diagnosis for all pa-
tients. Thrombocytopenia was defined as a platelet count < 150 × 109/
L12 and thrombocytosis as a platelet count ≥ 300 × 109/L.13,18,19 
Normal platelet count was defined as platelet count between 150-
299 × 109/L accordingly.
TA B L E  1   Demographic, clinical and staging information among hepatocellular carcinoma patients stratified by blood platelet count in the 
Taiwan cohort
Variables All patients Stratified by platelet count (109/L)
P value(Taiwan cohort) (n = 3561) <150 (n = 1727) 150-299 (n = 1513) ≥300 (n = 321)
Age (years), median (IQR) 65 (55-75) 66 (57-76) 65 (54-75) 60 (48-73) <.001
Male, % 77% 71% 82% 85% <.001
1 Aetiologies of chronic liver diseases  
(HBV/ HCV/alcohol/mixed/cryptogenic), %
40/22/5/18/15 37/29/5/19/10 43/16/5/16/20 42/12/8/17/21 <.001
Performance status (0/1/2-4), % 59/21/20 63/20/17 59/21/20 38/28/34 <.001
Mean/Median survival (months) 52/32 53/38 56/32 22/6 <.001
Tumour characteristics
Maximal size 0-2/2-5/5-10/≥10 cm, % 18/39/25/18 26/48/19/7 12/33/31/24 3/11/31/55 <.001
Maximal size, median (IQR), cm 4.3 (2.5-8.8) 3.2 (2.0-5.2) 6.0 (3.0-10.0) 11.0 (7.5-15.0) <.001
Multiple tumour, % 36% 37% 34% 41% 0.038
Any vascular invasion, % 24% 15% 29% 54% <.001
Distant/lymph node metastasis, % 11% 6% 12% 28% <.001
Laboratory values
Platelet (109/L), mean ± SD 170 ± 96 97 ± 33 206 ± 40 389 ± 80 <.001
Albumin (g/dL), mean ± SD 3.7 ± 0.6 3.6 ± 0.6 3.8 ± 0.6 3.5 ± 0.6 <.001
Bilirubin (mg/dL), mean ± SD 1.5 ± 2.8 1.6 ± 2.6 1.4 ± 2.8 2.0 ± 4.1 <.001
INR of PT, mean ± SD 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 <.001
AFP (ng/mL), median (IQR) 43 (8-769) 32 (9-247) 49 (7-1467) 720 (15-28815) <.001
Tumour staging
BCLC staging (0/A/B/C/D), % 8/25/16/40/11 11/31/15/34/9 6/22/19/41/12 1/4/14/60/21 <.001
Liver functional reserve
Child-Turcotte-Pugh class (A/B/C), % 73/22/5 71/24/5 78/18/4 61/33/6 <.001
Child-Turcotte-Pugh score, mean ± SD 6.1 ± 1.5 6.2 ± 1.6 5.9 ± 1.4 6.5 ± 1.6 <.001
ALBI grade (1/2/3), % 38/52/10 30/59/11 49/43/8 27/60/13 <.001
MELD score, mean ± SD 10.0 ± 4.4 10.3 ± 4.5 9.5 ± 4.2 10.4 ± 4.8 <.001
Note: hepatitis B surface antigen, HCV: positive for antihepatitis C virus antibody.
Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin-bilirubin grade; BCLC, Barcelona Clínic Liver Cancer; INR of PT, international normalized ratio 
of prothrombin time; IQR, interquartile range; MELD, model for end-stage liver disease; SD, standard deviation.
1HBV, positive for HBsAg, negative for anti-HCV Ab and no alcoholism; HCV, positive for anti-HCV Ab, negative for HBsAg and no alcoholism; 
alcohol: negative for HBsAg, negative for anti-HCV Ab, with alcoholism; mixed: at least two aetiologies including hepatitis B, hepatitis C and 
alcoholism; cryptogenic: negative for HBsAg, negative for anti-HCV Ab, with no alcoholism 
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2.3 | Statistics
We used the Kruskal-Wallis tests to compare continuous vari-
ables between three patient groups, while the χ2 and Fisher exact 
tests were utilized to compare categorical data. Median and over-
all survival was evaluated by the Kaplan-Meier method with log-
rank tests. We employed the Cox proportional hazard modelling 
to examine the adjusted hazard ratios (aHR) and 95% confidence 
intervals (CI) for each prognostic variable. Prognostic factors in-
cluding age, gender, liver disease aetiology, Child-Pugh score, maxi-
mal tumour size, tumour nodularity, vascular invasion, lymph node 
or distant metastasis, performance status, alpha-fetoprotein (AFP) 
and platelet count at diagnosis were included in univariable and 
multivariable analyses. Patients were censored at the time of liver 
transplantation or last visit if alive at the end of the study period or 
lost to follow-up.
As an exploratory analysis, we examined the possible non-lin-
ear relationship between platelet count and the hazards of mortality 
with restricted cubic splines.30,31 To test for non-linearity, we used 
a likelihood ratio test to compare a model consisting of linear terms 
with a model consisting of both linear terms and the cubic spline 
terms. A two-tailed P < .05 was considered statistically significant 
TA B L E  2   Demographic, clinical and staging information among hepatocellular carcinoma patients stratified by blood platelet count in the 
USA cohort
Variables All patients Stratified by blood platelet count (109/L)
P 
value(US cohort) (n = 1145) <150 (n = 717) 150-299 (n = 349) ≥300 (n = 79)
Age (years), median (IQR) 59 (55-65) 59 (54-64) 60 (55-66) 61 (56-67) .005
Male, % 78% 77% 78% 89% .049
Cirrhosis 1036 (90%) 705 (98%) 280 (80%) 51 (65%) <.001
1 Aetiologies of chronic liver diseases (HBV/ 
HCV/alcohol/mixed/cryptogenic), %
4/21/15/46/14 4/20/17/49/10 4/23/10/44/19 6/20/18/32/24 <.001
Race/ethnicity (NHW/H/AA/Asian/Other), % 34/28/32/5/1 37/33/25/4/1 30/19/42/7/2 25/17/52/6/0
Performance status (0/1/2-4), % 55/27/18 57/27/16 54/29/17 36/30/34 .001
Mean/Median survival (months) 32/15 34/16 31/14 14/4 <.001
Tumour characteristics
Maximal size 0-2/2-5/5-10/≥10 cm, % 17/40/22/21 21/45/22/12 11/36/22/31 1/14/22/63 <.001
Maximal size, median (IQR), cm 4.1 (2.4-8.7) 3.4 (2.2-6.1) 5.3 (2.8-11.8) 12.6 (7-17.4) <.001
Multiple tumour, % 47% 44% 48% 67% <.001
Any vascular invasion, % 29% 25% 33% 43% .001
Distant/lymph node metastasis, % 18% 12% 24% 47% <.001
Laboratory values
Platelet (109/L), mean ± SD 145 ± 93 90 ± 33 202 ± 40 394 ± 82 <.001
Albumin (g/dL), mean ± SD 3.3 ± 0.7 3.2 ± 0.7 3.5 ± 0.7 3.4 ± 0.6 <.001
Bilirubin (mg/dL), mean ± SD 2.0 ± 3.1 2.1 ± 2.8 1.8 ± 3.6 1.5 ± 2.2 <.001
INR of PT, mean ± SD 1.3 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.4 <.001
AFP (ng/mL), median (IQR) 42 (8-981) 33 (8-572) 48 (6-1628) 451 (15-10372) .005
Tumour staging
BCLC staging (0/A/B/C/D), % 6/37/17/24/16 6/41/16/18/19 5/34/18/31/12 0/15/19/48/18 <.001
Liver functional reserve
Child-Turcotte-Pugh class (A/B/C), % 49/38/13 40/44/16 63/30/7 63/32/5 <.001
Child-Turcotte-Pugh score, mean ± SD 7.1 ± 2.0 7.4 ± 2.0 6.5 ± 1.8 6.5 ± 1.4 <.001
ALBI grade (1/2/3), % 20/55/25 13/57/30 34/48/18 17/68/15 <.001
MELD score, mean ± SD 11.2 ± 5.0 11.9 ± 5.0 10.2 ± 4.9 9.9 ± 4.9 <.001
Abbreviations: AA, African American, AFP, alpha-fetoprotein, ALBI, albumin-bilirubin grade, BCLC, Barcelona Clínic Liver Cancer, INR of PT, 
international normalized ratio of prothrombin time, IQR, interquartile range, MELD, model for end-stage liver disease, NHW, non-Hispanics White, 
SD, standard deviation.
1HBV: positive for HBsAg, negative for anti-HCV Ab and no alcoholism; HCV: positive for anti-HCV Ab, negative for HBsAg and no alcoholism; 
alcohol: negative for HBsAg, negative for anti-HCV Ab, with alcoholism; mixed: at least two aetiologies including hepatitis B, hepatitis C and 
alcoholism; cryptogenic: negative for HBsAg, negative for anti-HCV Ab, with no alcoholism. 
2526  |     LIU et aL.
for all analyses. Statistical analyses were conducted using SAS 9.4 
(SAS Institute Inc, NC) and R 3.6.1 (R foundation, Vienna).
3  | RESULTS
3.1 | Patient and tumour characteristics
The cohort from Taiwan consisted of 3561 newly diagnosed HCC pa-
tients and the USA cohort included 1145 newly diagnosed patients. 
Baseline demographics are shown in Tables 1 and 2. The median age 
was 65 years in the Taiwan cohort and 59 years in the USA cohort, 
with the majority in both cohorts being male. As expected, the most 
common liver disease aetiology in the Taiwan cohort was HBV infec-
tion, while HCV infection accounted for most patients in the USA 
cohort. A total of 33% of patients in the Taiwan cohort and 41% of 
patients in the USA cohort had early-stage HCC (BCLC stage 0 or A).
3.2 | Thrombocytosis and tumour burden
A total of 1513 (42.5%) in the Taiwan cohort and 349 (30.4%) patients 
in the USA cohort had normal platelet count, while 1727 (48.5%) in 
the Taiwan cohort and 717 (62.7%) patients in the USA cohort had 
thrombocytopenia. Thrombocytosis was present among 321 (9.0%) 
of Taiwan patients and 79 (6.9%) of USA patients.
In both cohorts, patients with thrombocytosis were more likely 
to be male and had worse performance status, larger tumour size 
(Figure 1) and higher serum AFP levels (all P < .05). For patients with 
thrombocytosis, normal platelet count and thrombocytopenia, the 
median tumour size was 11.0 cm vs 6.0 cm vs 3.2 cm in the Taiwan 
cohort and 12.6 cm vs 5.3 cm vs 3.4 cm in the USA cohort respec-
tively (both P < .001). Patients with thrombocytosis also had higher 
vascular invasion (54% vs 29% vs 15% in the Taiwan cohort and 42% 
vs 33% vs 26% in the USA cohort) and increased lymph node involve-
ment or extra-hepatic distant metastases (28% vs 12% vs 6% in the 
Taiwan cohort and 48% vs 26% vs 12% in the USA cohort) respec-
tively (all P < .001). Overall, patients with thrombocytosis presented 
more frequently with late-stage HCC (81% in Taiwan and 66% in USA 
cohorts), compared to 43% and 37% late-stage HCC among thrombo-
cytopenic patients (both P < .001). In the USA cohort, HCC patients 
with thrombocytosis were less likely diagnosed by surveillance (11%) 
compared to 48% among thrombocytopenia patients (P < .001).
3.3 | Thrombocytosis, thrombocytopenia and 
overall survival
The median overall survival was 32 months and 15 months, respec-
tively, for Taiwan and USA cohorts. In both cohorts, overall survival was 
similar between thrombocytopenic patients and patients with normal 
platelet count, whereas patients with thrombocytosis had significantly 
worse survival (Figure 2). Patients with thrombocytosis had a median 
overall survival of 6 and 4 months in the Taiwan cohort and USA co-
hort, respectively, compared with 32 and 14 months for patients with 
normal platelet counts, and 38 and 16 months for patients with throm-
bocytopenia. In univariable Cox survival analysis, thrombocytosis was 
associated with increased mortality compared to those with normal 
platelet counts in the combined cohort (HR 2.31, 95% CI 2.04-2.62). 
Thrombocytosis remained a significant predictor for worse survival 
in multivariable analysis after adjusting for known prognostic factors 
including age, gender, liver disease aetiology, Child-Pugh score, maxi-
mal tumour size, tumour nodularity, vascular invasion, lymph node or 
distant metastasis, performance status and AFP level in Taiwan cohort 
(aHR 1.39, 95% CI 1.20-1.61) and in the USA cohort (aHR 1.70, 95% 
CI 1.25-2.31, Table 3). In the combined cohort, thrombocytosis was 
independently associated with adverse outcome (aHR 1.40, 95% CI 
1.23-1.60). Thrombocytopenia was also independently associated with 
worse survival in the combined cohort (aHR 1.13, 95% CI 1.04-1.23).
3.4 | Subgroup analyses: Thrombocytosis and 
overall survival
We combined the Taiwan and USA cohorts to examine the associa-
tion between platelet count and survival among subgroups (Table 4). 
We found a consistent association between thrombocytosis and poor 
prognosis across liver disease aetiologies, including HBV infection (aHR 
1.26, 95% CI 1.04-1.52), HCV infection (aHR 1.55, 95% CI 1.20-2.01), 
alcohol-related liver disease (aHR 1.40, 95% CI 1.09-1.79) and those 
with other aetiologies (aHR 1.72, 95% CI 1.28-2.31). We also found an 
association between thrombocytopenia and worse survival among pa-
tients with relatively preserved liver function (ALBI grade 1, aHR 1.21, 
95% CI 1.02-1.42, Figure 3, Table 4). On the contrary, thrombocytosis 
was associated with worse survival among patients with significant 
liver dysfunction (ALBI grades 2-3, aHR 1.38, 95% CI 1.19-1.60).
3.5 | Non-linear analysis between platelet 
count and overall survival
In a post-hoc exploratory analysis, we examined the non-linear as-
sociation between platelet count and overall survival among HCC 
patients in the combined cohort (Figure 4). Non-parametric regres-
sion suggested the platelet-survival relationship was non-linear in 
multivariable models (P for non-linearity < 0.001). The association 
appears to be non-linear among patients with relatively preserved 
liver function (ALBI grade 1, P for non-linearity = 0.022), and among 
patients with more significant liver dysfunction (ALBI grade 2 and 3, 
P for non-linearity = 0.041).
4  | DISCUSSION
Although thrombocytopenia has traditionally been associated 
with worse outcomes in patients with cirrhosis and HCC, platelets 
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are also actively involved in all aspects of carcinogenesis includ-
ing tumour growth, extravasation and metastasis.32 In this study, 
we recruited two large, well-characterized, HCC cohorts to exam-
ine the prognostic role of platelets in HCC patients. We found that 
thrombocytosis was associated with more advanced tumour burden 
and independently associated with worse survival after adjusting 
for age, gender, liver disease aetiology, Child-Pugh score, maximal 
tumour size, tumour nodularity, vascular invasion, lymph node or 
F I G U R E  1   Distribution of platelet count according to maximal tumor size in (A) Taiwan cohort, and (B) USA cohort of patients with 
hepatocellular carcinoma. Higher platelet counts were associated with larger tumour diameter in both cohorts
F I G U R E  2   Overall survival according to blood platelet count in (A) Taiwan cohort, and (B) USA cohort of patients with hepatocellular 
carcinoma. Thrombocytosis (platelet count ≥ 300 × 109/L) was associated with decreased survival in both cohorts
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distant metastasis, performance status and AFP level. The results 
were consistent across cohorts and liver disease aetiology. Further 
experimental and clinical studies are warranted to explore the chem-
oprophylactic, prognostic, and therapeutic role of platelets in HCC 
patients.
Our findings that thrombocytosis is associated with advanced 
tumour burden and potentially more aggressive tumour behaviour 
are in line with previous reports regarding the association between 
platelets and tumour stage.13,18,19 It is unclear if this difference is 
related to differences in tumour biology or simply related to differ-
ences in surveillance receipt. HCC surveillance is known to be a key 
driver of early tumour detection and is widely underused among 
at-risk patients.33-35 We only had surveillance data available for the 
USA cohort and patients with thrombocytosis were significantly 




HR (95% CI) for 
platelet < 150 × 109/L
1 Multivariable HR 
(95% CI) for platelet 
150-299 × 109/L
1 Multivariable 
HR (95% CI) for 
platelet ≥ 300 × 109/L
HBV related Positive for HBsAg 1996 1.12 (0.98-1.28) 1 [Reference] 1.26 (1.04-1.52)
HBV only Positive for HBsAg, negative 
for anti-HCV antibody, and no 
alcoholism
1462 1.21 (1.04-1.42) 1 [Reference] 1.32 (1.06-1.65)
HCV related Positive for Anti-HCV antibody 1804 0.99 (0.86-1.13) 1 [Reference] 1.55 (1.20-2.01)
HCV only Positive for anti-HCV antibody, 
negative for HBsAg, and no 
alcoholism
1026 1.05 (0.88-1.27) 1 [Reference] 1.76 (1.25-2.49)
Alcohol 
related
Positive for alcoholism 1361 1.01 (0.86-1.19) 1 [Reference] 1.40 (1.09-1.79)
Alcohol only Positive for alcoholism, 
negative for HBsAg and anti-
HCV antibody
347 1.66 (1.16-2.38) 1 [Reference] 1.62 (1.02-2.56)
Cryptogenic Negative for HBsAg and anti-
HCV antibody, no alcoholism
715 1.40 (1.13-1.73) 1 [Reference] 1.72 (1.28-2.31)
No liver 
dysfunction
Albumin-bilirubin grade 1 1573 1.21 (1.02-1.42) 1 [Reference] 1.18 (0.89-1.57)
Liver 
dysfunction
Albumin-bilirubin grade 2 and 3 3133 1.03 (0.94-1.14) 1 [Reference] 1.38 (1.19-1.60)
Abbreviations: CI, confidence interval, HBV, hepatitis B virus, HBsAg, hepatitis B virus surface antigen, HCV, hepatitis C virus, HR, hazard ratio.
1Additionally adjusted for age, gender, liver disease aetiology, Child-Pugh score, maximal tumour size, tumour nodularity, vascular invasion, lymph 
node or distant metastasis, performance status and alpha-fetoprotein level. 
F I G U R E  3   Overall survival according to blood platelet count in the combined hepatocellular carcinoma cohort. Thrombocytosis (platelet 
count ≥ 300 × 109/L) was associated with decreased survival among (A) all patients in the combined cohort, and (B) patients with preserved 
liver function (albumin-bilirubin grade 1). Among patients with significant liver dysfunction (C, albumin-bilirubin grade 2 and 3), platelet level 
was inversely related to overall survival
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less likely to be detected by surveillance. The lower surveillance re-
ceipt in these patients may relate to the under-recognition of cir-
rhosis, a common barrier to HCC surveillance in clinical practice.36 
Thrombocytosis has also been associated with worse survival among 
many other types of cancer8,9,32; however, to our knowledge, this 
is among the first reports confirming the prognostic implications of 
thrombocytosis among HCC patients. As platelet count is readily 
available in all HCC patients, the presence of thrombocytosis can 
serve as an important prognostic marker identifying patients who 
may benefit from more aggressive treatment, including antiplatelet 
therapies.18,22
Many existing reports on the relationship between platelet and 
liver diseases have focused on subjects with HBV infection. For ex-
ample, antiplatelet therapy has been shown to prevent HCC both in 
a mouse model and in patients with chronic hepatitis B.20,37-39 Our 
results confirmed the association between thrombocytosis and poor 
prognosis among HBV-infected patients; however, this association 
was independent of liver disease aetiology and consistent effect 
sizes were seen in patients with HCV, alcohol-related cirrhosis and 
other aetiologies. As platelets are closely involved in all steps of tum-
origenesis,32,40 additional research is warranted to reveal the roles of 
platelets in patients with HCC as a result of other aetiologies.
We also found that thrombocytopenia was a predictor of 
worse clinical outcomes. Thrombocytopenia, as a marker for por-
tal hypertension, is closely associated with liver dysfunction and 
overall survival. We thus performed post-hoc subgroup analysis 
based on the degree of liver dysfunction. Among patients with rel-
atively preserved liver function (ALBI grade 1), thrombocytopenia, 
but not thrombocytosis, was associated with decreased survival 
(Figure 4B, Table 4). On the other hand, among patients with more 
F I G U R E  4   Non-parametric restricted 
cubic splines of platelet count and 
hazard for mortality in the multivariable 
models in the combined hepatocellular 
carcinoma cohort among (A) all patients, 
(B) patients with relatively preserved 
liver function (albumin-bilirubin grade 
1) and (C) patients with more significant 
liver dysfunction (albumin-bilirubin grade 
2 and 3). We adjusted for age, gender, 
liver disease aetiology, Child-Pugh score, 
maximal tumour size, tumour nodularity, 
vascular invasion, lymph node or distant 
metastasis, performance status and 
alpha-fetoprotein level in the multivariable 
models
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significant liver dysfunction (ALBI grade 2 and 3), thrombocytosis, 
but not thrombocytopenia, was associated with worsening survival 
(Figure 4C, Table 4). One possible explanation is that among patients 
with preserved liver function, thrombocytopenia represented more 
severe portal hypertension, hence the decreased outcome. On the 
other hand, patients with more significant liver dysfunction would 
likely have background thrombocytopenia, and a “normal” platelet 
count could actually be an “elevated” platelet count, indicating an 
aggressive tumour behaviour. Taken together, these results suggest 
platelet count may not only serve as an indicator of portal hyper-
tension but also potentially as a dual marker of portal hypertension 
and tumour biology, thereby having varying prognostic implications 
among different patients.
Our study's findings call for further evaluation of the thera-
peutic roles of antiplatelet therapy in HCC patients. In a mouse 
model of ovarian cancer, thrombocytosis was the result of in-
creased hepatic thrombopoietin synthesis in response to tu-
mour-derived interleukin-6.8 The use of antiplatelet antibody 
reduced tumour growth in mouse models.8 It is interesting that 
sorafenib, the first targeted therapy in HCC patients, also har-
bours antiplatelet activity by inhibiting platelet-derived growth 
factor receptor β.41 The potential of antiplatelet therapy was 
demonstrated by studies showing that antiplatelet therapy was 
associated with improved HCC survival after surgical resection22 
and chemoembolization.42 Counteracting thrombocytosis either 
by directly targeting platelets, eg aspirin or NSAIDs, or indirectly 
via cytokines may be a new avenue of therapeutic options among 
HCC patients.
The study has certain inherent limitations. Although the study 
included HCC cohorts from Taiwan and the USA encompassing wide 
ranges of liver disease aetiologies, our results may not be general-
izable to other geographic areas. Second, although patients were 
enrolled consecutively in both cohorts, referral bias cannot be 
avoided completely. Third, platelet count was measured at a sin-
gle time point rather than serial measurements. We did not have 
serum information of pertinent biomarkers such as thrombopoietin 
and interleukin-6 levels in HCC patients, and could not elucidate the 
complex interaction between platelet and these cytokines. Fourth, 
we did not collect the administration of antiplatelet therapy be-
fore or after HCC diagnosis and could not evaluate the prognostic 
role of antiplatelet therapy among HCC patients. Finally, we do not 
have information about platelet size to examine its prognostic im-
plications. However, we feel that these limitations are outweighed 
by the study's strengths including its novelty, large multinational, 
well-characterized cohort and detailed granular data on tumour bur-
den and overall survival.
In conclusion, thrombocytosis was independently associated 
with more advanced tumour stage and worse overall survival among 
HCC patients. Our findings add to the growing literature about the 
complex interaction between platelets and HCC. Further transla-
tional studies are warranted in exploring the chemoprophylactic, 
prognostic and therapeutic roles of platelets and antiplatelet ther-
apy among HCC patients.
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APPENDIX A
STROBE Statement—checklist of items that should be included in reports of observational studies
Item No Recommendation Page
Title and abstract 1 (a) Indicate the study's design with a commonly used term in the title or the abstract 1-3




Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 4-5
Objectives 3 State-specific objectives, including any prespecified hypotheses 5
Methods
Study design 4 Present key elements of study design early in the paper 5-7
Setting 5 Describe the setting, locations and relevant dates, including periods of recruitment, 
exposure, follow-up and data collection
5-6
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection 
of participants
5-6
(b) Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed
Case-control study—For matched studies, give matching criteria and the number of controls 
per case
NA
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders and effect 




8* For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group
4-6
Bias 9 Describe any efforts to address potential sources of bias NA
Study size 10 Explain how the study size was arrived at 5-6
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why
6-7
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 6-7
(b) Describe any methods used to examine subgroups and interactions 6-7
(c) Explain how missing data were addressed 6-7
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy
6-7
(e) Describe any sensitivity analyses 6-7
Results
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up and 
analysed
5
(b) Give reasons for non-participation at each stage 5
(c) Consider use of a flow diagram NA
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders
7
(b) Indicate number of participants with missing data for each variable of interest NA
(c) Cohort study—Summarize follow-up time (eg average and total amount) 7
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Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8
Case-control study—Report numbers in each exposure category, or summary measures of 
exposure
NA
Cross-sectional study—Report numbers of outcome events or summary measures NA
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included
8-9
(b) Report category boundaries when continuous variables were categorized NA
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period
NA




Key results 18 Summarize key results with reference to study objectives 10
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias
12-13
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies and other relevant evidence
10-13
Generalizability 21 Discuss the generalizability (external validity) of the study results 10-13
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based
2
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of 
transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine 
at http://www.plosm edici ne.org/, Annals of Internal Medicine at http://www.annals.org/ and Epidemiology at http://www.epidem.com/). 
Information on the STROBE Initiative is available at www.strob e-state ment.org.
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort 
and cross-sectional studies.
